ChemicalBook > CAS DataBase List > PF-04691502

PF-04691502

Product Name
PF-04691502
CAS No.
1013101-36-4
Chemical Name
PF-04691502
Synonyms
CS-305;CS-2640;PF4691502;PF-04691502;PF 04691502; PF04691502;PF-04691502 ISO 9001:2015 REACH;PF-04691502, 98%, a potent and selective inhibitor of PI3K and mTOR kinases;2-Amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3;2-amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one;2-Amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one
CBNumber
CB22589602
Molecular Formula
C22H27N5O4
Formula Weight
425.48
MOL File
1013101-36-4.mol
More
Less

PF-04691502 Property

Melting point:
219-221°C
Boiling point:
682.5±65.0 °C(Predicted)
Density 
1.36
storage temp. 
Refrigerator
solubility 
Chloroform (Slightly, Heated, Sonicated), Methanol (Slightly, Sonicated)
form 
Solid
pka
14.39±0.10(Predicted)
color 
Pale Yellow to Light Green
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
PZ0235
Product name
PF-04691502
Purity
≥98% (HPLC)
Packaging
5MG
Price
$118
Updated
2024/03/01
Sigma-Aldrich
Product number
PZ0235
Product name
PF-04691502
Purity
≥98% (HPLC)
Packaging
25MG
Price
$462
Updated
2024/03/01
Cayman Chemical
Product number
15017
Product name
PF-04691502
Purity
≥95%
Packaging
5mg
Price
$89
Updated
2024/03/01
Cayman Chemical
Product number
15017
Product name
PF-04691502
Purity
≥95%
Packaging
10mg
Price
$142
Updated
2024/03/01
Cayman Chemical
Product number
15017
Product name
PF-04691502
Purity
≥95%
Packaging
50mg
Price
$578
Updated
2024/03/01
More
Less

PF-04691502 Chemical Properties,Usage,Production

Chemical Properties

Pale Yellow Solid

Uses

PF-04691502 is an potent and selective inihibitor of PI3K and mTOR Kinases with antitumor activity. Potent PI3K/mTOR Dual Inhibitor.

Uses

PF-04691502 is an ATP-competitive PI3K/mTOR inhibitor with IC50 of 32 nM and also inhibits Akt T308/S473 with IC50 of 7.5 nM/3.8 nM.

Biological Activity

pf-04691502 is a potent and selective dual pi3k/mtor (frap) inhibitor to phosphorylation of akt t308 (ic50 = 7.5 nm) and akt s473 (ic50 = 3.8 nm).[1]pi3ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer.the functions of pi3ks most relate to the ability of class i pi3k to activate protein kinase b (pkb, aka akt) as in the pi3k/akt/mtor pathway which is an intracellular signaling pathway directly related to cellular quiescence, proliferation, cancer, and longevity. there are many valuable anti-cancer drug treatment targets within this pathway. and also the p110δ and p110γ isoforms regulate different aspects of immune responses. [2]pf-04691502 is a potential medical drug that functions by inhibiting class i pi3k and mtor in the pi3k/akt/mtor pathway through fluorescence polarization kinase assay, cell,mice and other animal trials, and therefore, through inhibition, results in tumour suppression.[3,4] short-term exposure to pf-04691502 predominantly inhibits pi3k, whereas mtor inhibition persists for 24 to 48 hours. pf-04691502 induces cell cycle g(1) arrest, concomitant with upregulation of p27 kip1 and reduction of rb. [5] antitumor activity of pf-04691502 is observed in u87 (pten null), skov3 (pik3ca mutation), and gefitinib- and erlotinib-resistant non-small cell lung carcinoma xenografts. pf-04691502 inhibits tumor growth at 7 days by 72%. fdg-pet imaging revealed that pf-04691502 reduces glucose metabolism dramatically. tissue biomarkers of pi3k/mtor pathway activity, p-akt (s473), and p-rps6 (s240/244), are also dramatically inhibited following pf-04691502 treatment. [6]

Enzyme inhibitor

This ATP-competitive PI3K/mTOR dual inhibitor (FW = 325.49 g/mol; CAS 1013101-36-4; Solubility = 14 mg/mL DMSO, < 1 mg/ML H2O), also systematically named 2-amino-8-((1R,4R)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)- one, potently inhibits recombinant Class-I PI3Kα (Ki = 1.8 nM), PI3Kβ (Ki = 2.1 nM), PI3Kδ (Ki = 1.6 nM), PI3Kγ (Ki = 1.9 nM), and mTOR (Ki = 16 nM) in biochemical assays, with little activity against either Vps34, AKT, PDK1, p70S6K, MEK, ERK, p38, or JNK. PF-04691502 also suppresses avian fibroblast transformation mediated by wild-type PI3K γ, δ, or mutant PI3Kα. In PIK3CA-mutant and PTEN-deleted cancer cell lines, PF- 04691502 reduces phosphorylation of AKT T308 (IC50 = 7.5–47 nM) and AKT S473 (IC50 = 3.8–20 nM) and inhibits cell proliferation (IC50 = 180– 310 nM). PF-04691502 also inhibite mTORC1 activity within cells, asmeasured by PI3K-independent, nutrient-stimulated assay (IC50 = 32 nM) and inhibited the activation of PI3K and mTOR downstream effectors, including AKT, FKHRL1, PRAS40, p70S6K, 4EBP1, and S6RP. Shortterm exposure to PF-04691502 predominantly inhibits PI3K, whereas mTOR inhibition persists for 24 to 48 hours. PF-04691502 also induces cell cycle G1 arrest, concomitant with upregulation of p27 Kip1 and reduction of retinbalstoma protein, or Rb. At doses below the maximal tolerable dose, PD-0325901 potently inhibits tumor growth, when Kras and/or PI3K are drivers of tumor growth and progression.

References

1. yuan j."pf-04691502, a potent and selective oral inhibitor of pi3k and mtor kinases with antitumor activity". mol cancer ther, 2011, 10(11), 2189-2199.2. okkenhaug k. "signaling by the phosphoinositide 3-kinase family in immune cells.".annu. rev. immunol, 2013. 17 (2): 675–699.3. maira, sauveur-michel; stauffer, frédéric; schnell, christian; garcía-echeverría, carlos. "pi3k inhibitors for cancer treatment: where do we stand ". biochemical society transactions., 2009. 37 (pt 1): 265–72.4. kinross km. "in vivo activity of combined pi3k/mtor and mek inhibition in a krasg12d; pten deletion mouse model of ovarian cancer". mol cancer ther, 2011, 10(8), 1440-1449.5. yuan j, mol cancer ther, 2011, 10(11), 2189-21996. kinross km, mol cancer ther, 2011, 10(8), 1440-1449

PF-04691502 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

PF-04691502 Suppliers

Changzhou Chenhong Biotechnology Co., Ltd.
Tel
0519-85788828 13775037613
Email
sales@chemrenpharm.com
Country
China
ProdList
3574
Advantage
58
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2923
Advantage
55
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
94837
Advantage
76
Chembest Research Laboratories Limited
Tel
021-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6009
Advantage
61
Chemsky(shanghai)International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
32344
Advantage
50
Jinan Trio PharmaTech Co., Ltd.
Tel
+86 (531) 88811783
Fax
+86 (531) 55696010 QQ 1762738062
Email
sales@trio-pharmatech.com (International market)
Country
China
ProdList
1856
Advantage
62
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4668
Advantage
58
NCE Biomedical Co.,Ltd.
Tel
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax
+86-27-87599188
Country
China
ProdList
1494
Advantage
55
Nanjing Norris-Pharm Technology Co., Ltd
Tel
13901585132
Fax
+86-25-52131256
Email
799750417@qq.com
Country
China
ProdList
8888
Advantage
55
China Kouting Group Limited
Tel
+86 (21) 5811-6473 5811-6475
Fax
+86 (21) 6129-4103
Email
sales@koutingchina.com
Country
China
ProdList
496
Advantage
60
More
Less

View Lastest Price from PF-04691502 manufacturers

Dideu Industries Group Limited
Product
PF-04691502 1013101-36-4
Price
US $1.10/g
Min. Order
1g
Purity
99.00%
Supply Ability
100 Tons Min
Release date
2021-09-27
Career Henan Chemical Co
Product
PF-04691502 1013101-36-4
Price
US $2.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
100kg
Release date
2018-12-24

1013101-36-4, PF-04691502Related Search:


  • PF-04691502
  • 2-Amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one
  • 2-aMino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-Methoxypyridin-3-yl)-4-Methylpyrido[2,3-d]pyriMidin-7(8H)-one
  • PF-04691502 2-Amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one
  • PF4691502
  • 2-Amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3
  • PF-04691502, 98%, a potent and selective inhibitor of PI3K and mTOR kinases
  • CS-2640
  • CS-305
  • PF 04691502; PF04691502
  • Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-
  • 2-amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one
  • PF-04691502 ISO 9001:2015 REACH
  • 2-Amino-8-(rel-(1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one
  • 1013101-36-4
  • Akt
  • mTOR
  • PI3K
  • Inhibitors
  • PI3K/Akt/mTOR